logo

VTRS

Viatris·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --

VTRS fundamentals

Viatris (VTRS) released its earnings on Nov 6, 2025: revenue was 3.76B (YoY +0.24%), beat estimates; EPS was 0.67 (YoY -10.67%), beat estimates.
Revenue / YoY
3.76B
+0.24%
EPS / YoY
0.67
-10.67%
Report date
Nov 6, 2025
VTRS Earnings Call Summary for Q3,2025
  • Operational Growth: 1% Q3 revenue growth (ex-Indore), driven by generics and established brands.
  • Pipeline Momentum: Fast-acting meloxicam NDA submission by year-end; selatogrel/cenerimod enrollment on track.
  • Capital Allocation: $500M share buybacks YTD; $920M total capital returned in 2025.
  • Strategic Review: Multiyear cost savings with reinvestment in growth, details in Q1 2026.
  • Japan Expansion: Aculys acquisition adds CNS assets, strengthening innovative brands portfolio.
EPS
Revenue

Revenue & Expenses

VTRS has released its 2025 Q3 earnings report, with revenue of 3.76B, reflecting a YoY change of 0.23%, and net profit of -128.20M, showing a YoY change of -235.23%. The Sankey diagram below clearly presents VTRS's revenue sources and cost distribution.

Key Indicators

Viatris (VTRS) key financial stats and ratios, covering profitability, financial health, and leverage.
Viatris (VTRS)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.
Trend
Breakdown
Viatris (VTRS)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.
Trend
Breakdown
Viatris (VTRS)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.
Trend
Breakdown
Where does Viatris (VTRS) generate its revenue? Explore its key revenue streams and top earning regions.
By Business
Data source:
By Region
Data source:
Track Viatris (VTRS) Dividend Yield, Payout Ratio & Sustainability Through Its Dividend History
Payout Ratio
Dividend Yield